Global Trends in Health, Technology and Management II
Description
This book presents the proceedings of the 2nd International Symposium on Global Trends in Health, Technology, and Management (GTHTM-2025), held on February 15-17, Uttarakhand, India. It showcases the latest advancements in drug design and health, addressing some of the most pressing challenges in modern science and medicine. This book explores a wide range of topics, including emerging strategies in drug design and discovery, AI-powered drug development, and digital transformation in the health sector. It offers a blend of theoretical perspectives and practical case studies on translational approaches in drug development, predictive analytics, and advances in drug synthesis and chemistry.
Jointly organized by the Global Health Techno Management Forum (GHTMF) and the Global Institute of Pharmaceutical Education and Research (GIPER), this symposium builds on the success of previous conferences, fostering collaboration among leading scientists, industry experts, and policymakers.
These proceedings are a vital resource for researchers, professionals, and policymakers aiming to accelerate the development of safer, more effective therapies. It serves as a roadmap for future innovations in pharmaceutical sciences, guiding the way towards a healthier, more equitable world.
More details
Other editions
Additional editions
Persons
Anil Kumar Saxena, Chairman of the Global Institute of Pharmaceutical Education and Research, is a leading authority in Medicinal Chemistry and Computer-Aided Drug Design (CADD). Former Chief Scientist at CDRI, Lucknow, he has 50+ years of research experience, 230 publications, 72 patents, and has mentored 45 Ph.D. scholars. A pioneer of QSAR and CADD in India, Dr. Saxena is ranked among the top 2% scientists worldwide by Stanford University for five consecutive years. He is a Fellow of the Royal Society of Chemistry (UK), recipient of the Alexander von Humboldt Fellowship, and serves as Series Editor for Topics in Medicinal Chemistry (Springer). His editorial work includes Communicable diseases of the developing World- Vol. 29, Biophysical Tools in Computational Drug Discovery - Vol. 37 and GTHTM-2024 Proceedings.
Aaruni Saxena, MD, PhD, MRCP, MBA, is a clinician-researcher specializing in internal medicine, oncology, and clinical pharmacology. A Fellow of the United Nations and the International Society for Infectious Diseases, he has worked with the World Health Organization on global health strategies and clinical trial protocols.
Currently a Specialty Registrar in Oncology at Nottingham University Hospitals, Dr. Saxena holds dual medical certifications from Germany, a Ph.D. in Clinical Pharmacology, and an MBA in International Organizations from the University of Geneva. His research includes drug interactions, cardiovascular pharmacology, and molecular modeling, with multiple peer-reviewed publications.
Content
Innovations in Drug Design: Case Studies from Discovery to Development.- Development of Allosteric Inhibitors against Cyclin-Dependent Kinase 2 (CDK2).- Evaluation of 2-phenylthiazolidin-4-one analogues as inhibitors of the SARS-CoV-2 main protease.- Engineered Antibiotics: A Strategy to Combat Multi-Drug-Resistant Bacteria: A Review on Antibiotics Modification.- In silico studies of 1,2,4-triazole derivatives by targeting DHFR againsts staphylococcus aureus: Pharmacophore generation, Atom-based 3D-QSAR, Molecular docking and ADMET.- Rationale of Antifungal And Anti Bacterial Interventions Of Imidazole Derivatives.- Quantitative Structure Pharmacophore-Activity Relationship of Tricyclic Antidepressant (TCAs) Utilizing Distance-Based Features.- Computational Design of Pyrazole Derivatives for Management of Autoimmune Disease.- Designing, Synthesis and Characterization of Novel Heterocyclic Derivatives of-oxothiazolidine-3-carbonyl)-6- substituted-spiro[indoline-2,2'-thiazolidine]-3,4'-dione and -oxothiazolidine-3-carbonothioyl)-6- substituted-spiro [indoline-2,2'-thiazolidine]-3,4'-dione and their Bioevaluation.- Synthesis and Antimicrobial Evaluation of Novel dioxo spiro[indoline-3,2' thiazolidin]-3'-yl)thiourea and -dioxaspiro[indoline-3,2'-thiazolidin]-3'-yl)urea.